^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PM3023

    i
    Associations
    News
    Trials
    Company:
    BioNTech
    Drug class:
    CLDN18.2 inhibitor, T-cell stimulant
    Related drugs:
    Associations
    News
    Trials